Sales Performance - In 2025, the overall sales of Qianjiang Motorcycle in the fuel motorcycle industry were approximately 402,900 units, a year-on-year decline of about 8.1% [2] - Domestic sales were around 167,200 units, down approximately 20.9% year-on-year, with sales of models over 250cc at about 64,500 units, a decline of approximately 26% [2] - Exports reached approximately 235,700 units, showing a year-on-year growth of about 3.9%, with over 250cc models achieving sales of about 51,500 units, a growth of approximately 28.9% [2] 2026 Product Strategy - The main models for 2026 include racing, cruising, rally, and scooter series, with competitive products in the racing series such as 400, 550, 600, and 800cc [3] - The cruising series includes models of 250, 400, and 600cc, with some products featuring electronic throttle [3] Sales Strategy Adjustments - The sales strategy for 2026 focuses on: - **Public Opinion Management**: Building consumer trust through product reputation, service response, and quality commitments while addressing negative publicity [3] - **Focus on Bestsellers**: Reducing product variety to enhance quality and launching competitive models in racing, flash, rally, and scooter series [3] - **Sales Channel Reform**: Concentrating on the top 60 stores by sales, tracking operations, and replacing weak sales areas with self-operated models [3] - **Rapid Service Capability Development**: Enhancing user satisfaction by quickly addressing feedback and coordinating with service points and technical departments [3] Market Expansion Outlook - Anticipated steady growth in Europe, significant growth in South America and Southeast Asia, and breakthroughs in Africa for 2026 [3] Personnel Changes - Recent changes in the human resources department are due to personal reasons, with suitable candidates already identified for replacement, ensuring no impact on business operations [3] - Other personnel changes since 2025 include the marketing manager and quality director at QJMOTOR, reflecting normal organizational and talent optimization measures [3]

Financial Data and Key Metrics Changes - Total worldwide revenue in Q4 2025 was $22.6 million, a 5% decrease from $23.8 million in the same period last year, and a decrease of 7% on a constant currency basis [20] - Worldwide revenue for the full year 2025 was $90.5 million, an 8% increase over the prior year, and a 7% increase on a constant currency basis [20] - U.S. revenue in Q4 was $14.1 million, an 11% decrease from $15.9 million during the same period of the prior year [20] - International revenue in Q4 was $8.5 million, an 8% increase from $7.9 million during the same period last year [22] - Gross margin for Q4 was 77.6%, compared to 74% in the prior year [23] - Net loss for Q4 was $10.4 million or a loss of $0.25 per share, compared to a net loss of $13.2 million or a loss of $0.33 per share for the same period of the prior year [25] - Cash equivalents and marketable securities at the end of 2025 were $69.8 million, a decrease of $31.7 million from December 31, 2024 [26] Business Line Data and Key Metrics Changes - U.S. revenue for the full year 2025 was $57 million, a 1% increase over the prior year [21] - International revenue for the full year 2025 was $33.5 million, an increase of 23% over the prior year [22] - R&D expenses for Q4 were $4.6 million compared to $4 million in Q4 2024, reflecting increased clinical trial activity [24] - Sales, general, and administrative expenses for Q4 were $22.9 million compared to $27 million in Q4 2024 [24] Market Data and Key Metrics Changes - International growth was driven by continued strength in major European markets, offset by a lack of sales to the distributor in China [22] - The distributor in China is working through inventory from large orders placed in the first half of 2025, awaiting the renewal of the Chinese registration certificate expected in the second half of 2026 [22] Company Strategy and Development Direction - The company aims to re-accelerate U.S. sales growth, advance clinical initiatives, and align spending to deliver financial leverage towards profitability [7] - A focus on organizational alignment to optimize resources and decision-making in critical areas has been established [8] - The sales strategy is shifting to prioritize high-impact mandates and streamline the U.S. sales team's focus [10] - The AeriSeal program is a key focus for expanding the market, with the CONVERT II trial expected to complete enrollment in 2027 [15] Management's Comments on Operating Environment and Future Outlook - Management acknowledges that the underperformance in U.S. revenue was largely due to internal operational challenges and has begun implementing strategies to address these issues [7][8] - The company expects to deliver full-year 2026 revenue in the range of $90 million-$92 million, with a return to year-over-year growth anticipated in the back half of the year [26] - Management is confident in the business fundamentals and is focused on demonstrating meaningful operating leverage and reducing cash burn starting in 2026 [19][28] Other Important Information - A cost restructuring initiative has reduced ongoing operating expenses by over 10% [18] - A $60 million credit facility has been secured, extending the maturity of existing debt to 2031 and providing access to additional capital [18] Q&A Session Summary Question: What percentage of the sales force turned over in Q4? - The turnover was across the entire year, with approximately half of the sales organization experiencing turnover [31] Question: How are sales incentives structured now? - The design of the compensation plan has been adjusted to ensure it is reasonable and well-understood, with a focus on effective quota allocation [34] Question: Why wouldn't growth return sooner with the new sales force in place? - The company is starting from a position of decline, and new reps require time to ramp up productivity [41] Question: What areas contributed to the 10% cost reduction? - Most savings came from G&A and marketing, while maintaining investments in key growth areas like sales and R&D [46] Question: How will AeriSeal and the CONVERT II trial be balanced with U.S. sales investments? - The company believes that the trial's execution will not significantly impact overall spending and will be aligned with commercial operations [52] Question: What is the status of sales in China? - Sales to China are expected to resume in the back half of 2026, with minimal contributions anticipated in the first half [78]

Core Insights - ST Sairong reported a significant decline in both revenue and net profit for 2024, indicating increased operational pressure due to market competition and policy adjustments in the pharmaceutical industry [1][3][5] Revenue and Profit Performance - The company's total revenue for 2024 was 264 million, a year-on-year decrease of 15.15% from 311 million in 2023 [1][3] - The net profit attributable to shareholders was -33 million, a drastic decline of 447.67% compared to the previous year [1][3] - The net profit after excluding non-recurring gains and losses was -33.5 million, reflecting a staggering drop of 1275.25% [1][3] R&D Investment and Outcomes - Despite increasing R&D investments, the conversion of these efforts into financial improvement has been limited [4] - The company received approval notifications for 12 raw materials, including hydrochloride esmolol and fluorouracil, and completed registrations for several injectable formulations [4] - The low efficiency in converting R&D outcomes into market competitiveness has exacerbated the company's financial burden [4] Market Competition and Sales Strategy - The pharmaceutical industry faced intensified competition in 2024, driven by policy changes and expanded centralized procurement [5] - ST Sairong adjusted its sales strategies to enhance market share and optimize product sales structure, but these efforts yielded limited results due to fierce competition [5] - Although sales and management expenses decreased, this reduction did not significantly improve net profit performance [5]